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TimelinessBackground: To minimise vaccine-associated risk of intussusception following rotavirus vaccination,
Norway adopted very strict age limits for initiating and completing the vaccine series at the time rota-
virus vaccination was included in the national immunisation programme, October 2014. Although
Norway has a high coverage for routine childhood vaccines, these stringent age limits could negatively
affect rotavirus coverage. We documented the status and impact of rotavirus vaccination on other infant
vaccines during the first year after its introduction.
Methods: We used individual vaccination data from the national immunisation register to calculate cov-
erage for rotavirus and other vaccines and examine adherence with the recommended schedules. We
identified factors associated with completing the full rotavirus series by performing multiple logistic
regression analyses. We also evaluated potential changes in uptake and timeliness of other routine vac-
cines after the introduction of rotavirus vaccine using the Kaplan-Meier method.
Results: The national coverage for rotavirus vaccine achieved a year after the introduction was 89% for
one dose and 82% for two doses, respectively. Among fully rotavirus-vaccinated children, 98% received
both doses within the upper age limit and 90% received both doses according to the recommended sched-
ule. The child’s age at the initiation of rotavirus series and being vaccinated with diphtheria, tetanus, per-
tussis, polio and Haemophilus influenzae type b (DTaP/IPV/Hib) and pneumococcal vaccines were the
strongest predictors of completing the full rotavirus series. No major changes in uptake and timeliness
of other paediatric vaccines were observed after introduction of rotavirus vaccine.
Conclusions: Norway achieved a high national coverage and excellent adherence with the strict age limits
for rotavirus vaccine administration during the first year of introduction, indicating robustness of the
national immunisation programme. Rotavirus vaccination did not impact coverage or timeliness of other
infant vaccines.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In October 2014, the two-dose oral Rotarix vaccine
(GlaxoSmithKline Biologicals, Rixensart, Belgium) was introduced
in the Norwegian immunisation programme. Current European
guidelines from 2014 recommend initiating rotavirus vaccination
between 6 and 8 weeks of age and completing the entire series
by 24 weeks of age due to age-specific vaccine-associated risk of
intussusception following vaccination [1,2]. The previous version
of these guidelines recommended the first rotavirus dose to be
given between 6 and 12 weeks of age and completing the entire
vaccine series by the age of 27 weeks [3]. The World HealthOrganization recommends an upper age limit of 15 weeks for the
first rotavirus dose and a maximum age of 36 weeks to complete
the full series [4]. The upper age limits for vaccination are recom-
mended because of a risk of intussusception following rotavirus
vaccination [5–7]. The baseline annual incidence of intussuscep-
tion in Norway before rotavirus vaccine introduction was esti-
mated at 3.7 (95% CI 3.3–4.2) cases per 10,000 children <2 years
of age [8]. To minimise vaccine-associated risk of intussusception,
Norway was the first among all industrialised countries to adopt
the strictest age limits for initiating and completing the vaccine ser-
ies. Thus, the initiation of rotavirus vaccination is recommended at
6 weeks of age with the second dose given at 12 weeks of age. The
Norwegian absolute upper age limit for the first dose is 12 weeks
(84 days) and for the second dose is 16 weeks (112) days. An
interval of at least 4 weeks (28 days) is recommended between
the two doses.
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2014, Norway had a consistently high uptake for other childhood
vaccines included in the national immunisation programme (e.g.
P93% for the third dose of diphtheria, tetanus, pertussis, polio
and Haemophilus influenzae type b vaccine (DTaP/IPV/Hib) at
2 years of age). However, a recent study found that at least one
routine vaccination was slightly delayed in 45% of Norwegian chil-
dren aged 62 years [9]. The stringent age cut-offs for rotavirus vac-
cine administration could negatively affect its uptake, but delayed
rotavirus vaccination could affect vaccine safety and potentially
jeopardize sustainability of the entire immunisation programme.
Thus, a timely assessment of both vaccine coverage and adherence
with the recommended age limits is crucial to ensure the adequate
implementation, performance and safety of a newly introduced
immunisation programme.
The aim of this study was to document the status and impact—
on other vaccines—of rotavirus vaccination in Norway during the
first year after its inclusion in the national immunisation pro-
gramme, and to identify predictive factors for completion of the
two-dose vaccination course.2. Materials and methods
2.1. Data source and study population
We obtained data from the Norwegian Immunisation Register
(SYSVAK), a national, electronic immunisation register which uses
population census data as a denominator to estimate vaccine cov-
erage [10]. Reporting to SYSVAK is mandatory for all programme
vaccines and is based on a unique personal identification number
assigned to all legal residents in Norway. Immunisation providers
report the following data to SYSVAK: personal identification num-
ber, birth date, sex, administration date for each vaccine dose,
vaccine-specific code (a reporting code assigned by the register
to differentiate between various vaccines), name and municipality
of the immunisation provider, and reporting date. Nearly all provi-
ders (99%) report data electronically in real time by transferring
information to SYSVAK through a secure link. The remaining 1%
report by using paper forms; these data are entered manually.
The completeness of reported data is high, as 98% of the annual
birth cohorts (n  60,000) are registered in SYSVAK.
For this study, we used two cohorts of children: a pre-
rotavirus vaccine cohort and a post-rotavirus vaccine cohort.
The pre-rotavirus vaccine cohort consisted of all children born
from 1 September 2009 through 31 August 2014 or during five
years before the introduction of rotavirus vaccine. The post-
rotavirus vaccine cohort includes children born from 1 September
2014 through 31 August 2015; the first annual cohort eligible to
receive rotavirus vaccine within the national programme. For the
post-rotavirus vaccine cohort, data extraction and evaluation was
done on a weekly basis during January–December 2015 to ensure
that the each member of the cohort was age-eligible for vaccina-
tion. Immunisation status and time of vaccination for each child
were first evaluated when the child had reached 16 weeks of
age and re-evaluated on a weekly basis until the end of study
period.
If multiple vaccinations targeting the same diseases were
recorded on the same date, only one vaccination was included in
the analysis. If more than two rotavirus doses were recorded for
the same child, information about only the first two doses was
included in the analysis. This is because multiple reporting to SYS-
VAK is possible even though the national programme offers only a
two-dose rotavirus vaccine. We calculated age at vaccination for all
received doses and intervals between doses using the birth date
and administration dates for each dose.2.2. Coverage, timeliness and completeness of rotavirus vaccination
Rotavirus vaccine coverage was calculated from January 2015 to
December 2015 using the post-rotavirus vaccine cohort. We calcu-
lated the general coverage for rotavirus vaccination by using the
total number of children who had received the vaccine as the
numerator and the number of children born in Norway during
the study period as the denominator. Both the numerator and
the denominator included only children who were 16 weeks and
older at the time of each data extraction because 16 weeks is the
maximum recommended age for a two-dose rotavirus vaccine
course in Norway [8]. We examined timeliness of rotavirus vacci-
nation by calculating a time-dependent coverage. The latter was
calculated by restricting the numerator to children who received
dose one by age 12 weeks and dose two by 16 weeks of age. We
assessed adherence with the recommended schedule by restricting
the numerator to children who received dose one between 6 and
12 weeks of age and dose two by age 16 weeks, including an inter-
val of at least 4 weeks between the doses. The proportions of chil-
dren vaccinated before reaching the lower age limit of 6 weeks or
outside the upper age limit of 16 weeks were also calculated.
We evaluated differences in the rotavirus vaccine coverage by
sex and geographic regions using a chi-square test. For the latter,
data were divided into five regions: Northern, Central, Western,
Southern and Eastern. In addition, we assessed the relationship
between completeness of rotavirus schedule and a set of predictor
variables. Rotavirus vaccination status was defined as partially vac-
cinated if only one rotavirus dose was administrated or fully vacci-
nated if two rotavirus doses were administrated. The set of
predictor variables included age at administration for rotavirus
dose one, sex, geographical region, having received at least one
dose of DTaP/IPV/Hib, pneumococcal or hepatitis B vaccines, and
having received one dose of Bacillus Calmette-Guerin (BCG) vac-
cine. Socio-economic characteristics such as parental educational
status or household income are not available in the immunisation
register. To explore the association between rotavirus vaccination
status and each of these predictor variables, we first performed a
univariate logistic regression analyses; Odds Ratios (ORs) and their
95% confidence intervals (95% CIs) were calculated. Variables found
to be associated in the univariate models at the threshold of p < 0.1
were entered into multiple logistic regression models through a
forward stepwise selection process and retained if their inclusion
produced a significant likelihood ratio test result (p < 0.05) as com-
pared to the previous model. ORs and their 95% CIs were calculated
for the final adjusted model. Statistical significance for the multiple
logistic regression model was determined by setting a conservative
Bonferroni corrected threshold of p < 0.05/M, where M denotes the
number of explanatory variables included in the final adjusted
model.
2.3. Comparison between rotavirus vaccine and other programme
vaccines
We assessed uptake for other childhood programme vaccines
such as the BCG and hepatitis B vaccines, which Norway offers to
children whose parents originate from areas with high endemicity
of tuberculosis or hepatitis B virus infection. Simultaneously with
the introduction of rotavirus vaccine, timing of BCG vaccination
was moved from birth to 6 weeks of age per modified national rec-
ommendations. In addition, we calculated coverage of dose one for
DTaP/IPV/Hib vaccine and dose one of pneumococcal vaccine and
compared coverage for these vaccines with a two-dose coverage
for rotavirus vaccine. Both DTaP/IPV/Hib and pneumococcal
vaccines should be administered concomitantly with the second
rotavirus dose before age 16 weeks in the Norwegian programme.
Coverage for these vaccines was calculated by using the same
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described above for rotavirus vaccine.
2.4. Impact of rotavirus vaccine introduction on other infant vaccines
We examined differences in uptake and timeliness of other
paediatric vaccines between the pre- and post-rotavirus vaccine
periods. For pre-rotavirus vaccine period, data were divided into
five birth cohorts; each cohort included children born during 1
September–31 August annually. Immunisation data were used
for all children with information on the birth date and dates of vac-
cination. We ensured that all children included in the analysis
were age-eligible for vaccination by evaluating immunisation data
for children who were 16 weeks of age or older by the end of each
study period (i.e. 31 August). If a child was not vaccinated by the
end of the study period, the child was considered as right-
censored. For each vaccine included in the study, timeliness and
coverage at any given age were estimated by the Kaplan–Meier
(KM) method using age at vaccine administration as the time scale
[11]. The KM method estimates the survival function, KMSðtÞ, for
each age interval, t, as the proportion of children unvaccinated at
the end of the age interval divided by those unvaccinated at the
beginning of the age interval. The immunisation coverage at any
given time is calculated by the inverse of survival function,
1 KMSðtÞ [12].
All analyses were performed using the statistical software
STATA, version SE13 (StataCorp LP, College Station, TX, USA).
3. Results
3.1. Coverage, timeliness and completeness of rotavirus vaccination
From January 2015 to December 2015, rotavirus vaccine cover-
age in Norway increased from 77% to 89% for one dose and from
65% to 82% for two doses. We observed no differences by sex
for either one or two doses. However, there were significant
differences in the coverage by geographical regions for both doseTable 1





Age at vaccine administrationa Age at vaccine administration 0,90
DTPa Not vaccinated (ref)
Vaccinated 60,48
BCGa Not vaccinated (ref)
Vaccinated 1,08
HEPa Not vaccinated (ref)
Vaccinated 0,84







OR: Odd ratios and 95% confidence intervals for OR’s; p-val: p-values obtained from log
a Variables included in the final multiple logistic regression models; Ref: reference
between rotavirus vaccine status and explanatory variables in the multiple logistic reg
number of variables included in the final multiple logistic regression model. DTP: dipht
PNE: pneumococcal vaccine; BCG: Bacillus Calmette-Guerin vaccine.one (v2 = 81,2, df = 4, p < 1 1016) and dose two (v2 = 126.3,
df = 4, p < 1 1016). The highest coverage was achieved in Eastern
Norway: 90% for dose one and 84% for two doses. The lowest cov-
erage ranged from 87% in the Northern part for one dose to 79% in
the Southern part for two doses.
Among all children who received two rotavirus doses
(n = 50,495), the mean age at vaccination was 6.8 weeks (median:
6.6; IQR: 6.2–7.2) for dose one and 13.5 weeks (median: 13.3;
IQR: 13–13.8) for dose two. Ninety-eight percent of vaccinees
received both rotavirus doses within the upper age limits, reflect-
ing satisfactory timeliness. Of 60,862 children who received at
least one rotavirus dose, 96% were vaccinated by age 12 weeks
and 90% were immunised between 6 and 12 weeks of age. A total
of 4038 infants (7% of all children vaccinated with at least one
rotavirus dose) received rotavirus vaccine before the recom-
mended age of 6 weeks, but age at vaccination in 75% of these chil-
dren was between 5.6 and 5.9 weeks. In addition, 927 children
(2% of all children vaccinated with two rotavirus doses) received
the second dose after the recommended upper age limit of
16 weeks, 75% of these children were vaccinated before 18 weeks
of age. Considering the proportion of children immunised within
the upper age limits, a time-dependent coverage for rotavirus vac-
cine reached 86% for one dose and 81% for two doses within the
first year of introduction. Overall, 90% (n = 45,826) of vaccinated
children were immunised within the recommended age and with
a correct interval between doses (at least 28 days), demonstrating
a high adherence with the national recommendations.
Both the univariate and multiple logistic regression analyses
indicated that there was an association between being fully vacci-
nated for rotavirus and infant’s age at the initiation of rotavirus
vaccine series as well as receiving at least one dose of DTaP/IPV/
Hib, pneumococcal and BCG vaccines. Receiving at least one dose
of hepatitis B vaccine was negatively associated with being fully
vaccinated against rotavirus. Children residing in the Western
and Southern Norway were also less likely to complete the rota-
virus vaccine course compared to children living in the Eastern
region of the country (Table 1).nation, Norway.
ogistic regression Multiple logistic regression
[95% CI] p-val OR [95% CI] p-val
0,89 1,01 0,12
0,90 0,91 <0.001 0,90 0,90 0,90 <0.001
48,82 74,93 <0.001 49,76 34,74 71,29 <0.001
1,00 1,17 0,06 1,35 1,12 1,63 0,001
0,78 0,90 <0.001 0,58 0,49 0,69 <0.001
13,92 17,93 <0.001 3,77 2,77 5,12 <0.001
0,66 0,82 <0.001 0,90 0,77 1,06 0,21
0,83 1,07 0,36 0,81 0,69 0,95 0,01
0,60 0,78 <0.001 0,85 0,70 1,04 0,12
0,70 0,82 <0.001 0,78 0,70 0,86 <0.001
istic regression models.
group used in the logistic regression model. Bold indicates significant association
ression model using a Bonferroni corrected threshold of p < 0.05/M, where M = 6,
heria, tetanus, pertussis, inactivated polio, haemophilus influenzae type b vaccine;
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vaccines
3.2.1. DTaP/IPV/Hib and pneumococcal vaccines
During the first year of rotavirus vaccine introduction, coverage
for dose one of DTaP/IPV/Hib vaccine among children also eligible
for rotavirus vaccination was higher (95%) than rotavirus coverage
for dose two (82%). Of 47,419 children vaccinated with both vacci-
nes during this period, 92% were immunised concomitantly. Differ-
ences in coverage between rotavirus vaccine and DTaP/IPV/Hib
vaccines varied across Norway with the largest difference (16%)
found in the Southern part of Norway and the smallest (12%) in
Eastern Norway. The difference in coverage between these two
vaccines reduced over time. The proportion of children vaccinated
with two rotavirus doses among those receiving one dose of DTaP/
IPV/Hib vaccine increased from 77% in January 2015 to 86% in
October 2015, suggesting an improved performance of the immu-
nisation programme over time. Coverage of pneumococcal vaccine
during the first year of rotavirus vaccine was very similar to DTaP/
IPV/Hib vaccine.
3.2.2. BCG and hepatitis B vaccines
By December 2015, 11,087 (20%) children born from 1 Septem-
ber 2014 to 31 August 2015 and eligible for rotavirus vaccination
were BCG immunised. Among these children, 93% also received
at least one rotavirus dose and 50% received both vaccines con-
comitantly with the mean age at vaccination of 6.8 weeks (median:
6.7; IQR: 6.3–7.3). Among the same cohort of children, 12,642
received one dose of hepatitis B vaccine, 11,385 received two dosesFig. 1. Cumulative vaccination coverage (inverse Kaplan-Meier curves) with DTP: dipht
PNE: pneumococcal vaccine; BCG: Bacillus Calmette-Guerin vaccine during pre-rotaviruand 5269 received three doses. Of the children that received at
least one dose of hepatitis B vaccine, 91% received also one rota-
virus dose and 80% received two rotavirus doses.3.3. Impact of rotavirus vaccine introduction on other infant vaccines
We compared coverage and timeliness of other infant vaccines
during the pre- and post-rotavirus periods and observed no differ-
ences between the two periods (Fig. 1). The mean age at vaccina-
tion was 13.5 weeks for the DTaP/IPV/Hib vaccine and
pneumococcal vaccines during both study periods; 90% of children
were vaccinated with these vaccines before age 16 weeks during
both pre- and post-rotavirus periods.
The proportion of children vaccinated with the BCG vaccine was
also similar during the pre-rotavirus period (19%) to the proportion
estimated during the first year after the introduction of rotavirus
vaccine (20%). Therewas a change in the age at BCG vaccination dur-
ing the post-rotavirus period, with one half of all children receiving
the vaccine by 6.7 weeks of age compared to the same proportion
being vaccinated by 1.7 weeks of age during the pre-rotavirus per-
iod. This change is likely a result of modifying the recommended
age for BCG vaccination from birth to 6 weeks, which was intro-
duced in Norway simultaneously with rotavirus vaccination.4. Discussion
A year after the inclusion of rotavirus vaccine in the national
immunisation programme, Norway achieved a highly satisfactoryheria, tetanus, pertussis, inactivated polio, haemophilus influenzae type b vaccine;
s vaccine and post-rotavirus vaccine periods, Norway.
4688 B. Valcarcel Salamanca et al. / Vaccine 34 (2016) 4684–4689coverage compared to other industrialised countries [13–15]. From
January 2015 to December 2015, rotavirus vaccine coverage was
77–89% for dose one and 65–82% for dose two. Adherence with
the national recommendations for the rotavirus vaccination sched-
ule was also very high for each of the two doses; 98% of children
received both doses within the upper age limits, and 90% were
immunised per national recommendations. Such high adherence
with the rigid age limits for a newly introduced vaccine is indeed
impressive. To our knowledge, Norway is the only industrialised
country at present that adopted such strict age limits in the
national programme in order to reduce vaccine-associated risk of
intussusception. Such risk mitigation strategy has not been pur-
sued elsewhere due to feasibility issues and concerns about reach-
ing a high coverage. Since rotavirus vaccine introduction in 2014,
no signal of increased intussusception incidence has been identi-
fied. However, a detailed assessment of the post-introduction inci-
dence of intussusception over a longer period is required to fully
evaluate the benefits of a strict administration schedule.
Completing rotavirus vaccine series is critical to increase vac-
cine effectiveness and provide full protection against rotavirus dis-
ease. In Norway, a high completeness of vaccine series was
obtained throughout the first introduction year: 92% of children
who received one rotavirus dose also received dose two. Because
of the strict age limits established in the Norwegian programme,
children that were delayed with dose one, were less likely to com-
plete the full vaccine series.
Despite rapidly achieved high coverage for rotavirus vaccine, it
was still 13% lower at the end of the first introduction year com-
pared with coverage for other childhood vaccines such as the
DTaP/IPV/Hib and pneumococcal vaccines. A similar phenomenon
was reported from other countries that introduced rotavirus vacci-
nation [16]. The strict age recommendations for rotavirus vaccina-
tion are a likely explanation for a lower rotavirus coverage
compared with other routine immunisations. Other explanations
are lower community acceptance, vaccine hesitancy, and safety
concerns about a newly introduced vaccine [17,18]. Differences in
coverage between rotavirus and other programme vaccines varied
across the country with the largest difference found in the Southern
part. Because organisation and delivery of immunisation services in
Norway is a local responsibility, regional differences in coverage
could be explained by different implementation routines in various
regions and delays in reporting of immunisation data [10].
Previous studies have shown an improvement in the timeliness
of other paediatric vaccines after the introduction of rotavirus vac-
cine in the national immunisation programme [19,20]. However, a
year of rotavirus vaccine use in Norway did not seem to influence
timeliness of the DTaP/IPV/Hib, pneumococcal or hepatitis B vac-
cines. We found a shift in the age at vaccination with the BCG vac-
cine after introduction of rotavirus vaccine, which is likely due to
the modified national BCG recommendations. The inclusion of
rotavirus vaccine also did not influence the coverage of other pae-
diatric vaccines during the first post-introduction year, demon-
strating that uptake of other vaccines was not jeopardized by the
introduction of a new oral vaccine with strict age limits for admin-
istration. Interestingly, we found that children vaccinated against
hepatitis B virus infection were less likely to complete the full rota-
virus series. As hepatitis B vaccination is currently offered only to
children with immigrant parents, it is possible that socioeconomic
and cultural determinants in this population affect immunisation
rates, in particular for newly introduced vaccines.
The strength of our study is the use of individual immunisation
data from a national population-based register, which is the most
robust source for estimating population-based vaccine coverage.
The Norwegian immunisation register is among the most devel-
oped electronic immunisation registries in Europe [10]. The valid-
ity and completeness of data are ensured through mandatoryreporting of all programme vaccines and an extensive quality
assurance programme. Despite using highly robust immunisation
data, coverage for rotavirus and other vaccines in our study may
have been underestimated. Miscoding of newly introduced vacci-
nes can occur, especially at the start of introduction, if a reporting
code for a new vaccine is missing in the medical records’ system
used by immunisation providers or if providers are not aware of
a new vaccine. Underreporting is also possible because vaccina-
tions are reported using a personal identification number, and
some infants may not be assigned such numbers at the time when
they were eligible to receive the first rotavirus dose. In this case,
vaccination is reported using a temporary personal identification
number but unless reported data are updated by the provider after
the permanent personal identification is assigned, there will be a
mismatch between the provider’s system and the register. This
may reduce our estimates of rotavirus vaccine coverage, especially
for two doses, because when only one dose is reported, a child
would be included in the coverage estimates for one dose but
not in the estimates for two doses even though he or she may have
received two doses.
5. Conclusion
This study provides the first insight into the performance of
rotavirus vaccination programme since its introduction in Norway.
High vaccine coverage together with a highly satisfactory adher-
ence with the strict age recommendations was achieved during
the first year of introduction, indicating feasibility of such vaccina-
tion strategy and robustness of the Norwegian immunisation pro-
gramme. Introduction of rotavirus vaccination did not affect
coverage or timeliness of other infant vaccines.
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